Request Investor Info

Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

May 3, 2023

Investing in healthcare

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology. The technology helps bio drugs overcome intracellular barriers, making them more effective. Defence is excited about three upcoming clinical trials, expected to start by the end of the year, which will be important for the company's growth. Defence is also actively working to license their technology to other companies. The mRNA therapeutics market is projected to reach close to $130 billion by 2030, making the potential for Defence's growth promising.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.

‍

Latest Articles

Centurion CEO Romundt Sees Generational Opportunity in Real Estate Finance

TD Q U.S. Small-Mid-Cap Equity ETF Offers an Investment Opportunity Not Seen in a Long Time ETFs

Mission Critical: How XPhyto Therapeutics Could Revolutionize PCR Testing Cannabis

Algernon Pharmaceuticals: Investigating a Novel Therapy for Stroke Patients Using the Psychedelic Drug N,N-Dimethyltryptamine (DMT)Healthcare

Hot Companies

Aston Bay Holdings

KITS Eyecare Ltd.

You might also like

Lexaria Bioscience: Transforming GLP-1 Drug Delivery for a Growing Market

Lexaria Bioscience is advancing GLP-1 drug delivery, aiming to improve effectiveness and reduce side effects for this fast-growing market.

Sernova: Advancing the Future of Diabetes Treatment

Sernova's clinical trials for type 1 diabetes have led to multiple patients achieving insulin independence and stable long-term blood sugar levels.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!